Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Eton Pharmaceuticals, Inc ("ETON" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.

To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.

About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ETON
The Conversation (0)

Eton Pharmaceuticals Announces Availability of Biorphen Injection

Eton Pharmaceuticals (NASDAQ:ETON) has announced that the Biorphen to treat hypotension from vasodilation in the setting of anesthesia is now commercially available. As quoted in the press release: Biorphen is available in a 5mL ampule containing 500mcg of phenylephrine. The product is now... Keep Reading...

Interactive Chart

Latest Press Releases

Related News